查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1967585

人工智慧在心臟病学领域的市场－全球产业规模、份额、趋势、机会、预测：按组件、应用、地区和竞争对手划分，2021-2031年

Artificial Intelligence in Cardiology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球人工智慧 (AI) 驱动的心臟病学市场预计将从 2025 年的 8.3887 亿美元成长到 2031 年的 16.6556 亿美元，复合年增长率达到 12.11%。

该领域利用机器学习演算法和计算分析来解读复杂的心血管数据，从而促进疾病的早期发现并制定个人化的治疗方案。推动该市场成长要素包括全球心臟病负担的日益加重，以及随着患者数量的增长而对简化临床工作流程的需求。此外，医疗专业人员对数位健康工具信心的增强也是推动成长的因素之一；根据美国医学会 (AMA) 2024 年的报告，66% 的医生在其诊疗实践中使用医疗人工智慧，与上年度相比，采用率显着提高。

市场概览
预测期 2027-2031
市场规模：2025年 8.3887亿美元
市场规模：2031年 16.6556亿美元
复合年增长率：2026-2031年 12.11%
成长最快的细分市场 软体解决方案
最大的市场 北美洲

然而，市场在资料隐私和严格的监管合规方面面临许多挑战。演算法训练需要处理大量敏感的患者数据，这引发了安全隐患，并要求遵守严格的法律标准。这可能会延缓新解决方案的核准和部署。这些合规义务实际上减缓了创新步伐，并严重阻碍了这些先进诊断技术快速融入标准临床护理。

市场驱动因素

心血管疾病发生率的上升是推动心臟病学领域采用人工智慧的主要动力，也因此需要更先进的工具来应对日益增长的临床和经济负担。随着患者群体老化和心臟病复杂性的增加，医疗系统正在利用人工智慧实现诊断流程的自动化，降低误诊率，并减轻长期心臟护理成本的上升。美国心臟协会2024年6月发布的《预测2050年美国心血管疾病和中风负担》建议强调了这一转变的紧迫性，该报告预测，到2050年，心血管疾病总成本将增长两倍，达到1.8万亿美元。因此，医院正积极采用人工智慧驱动的预测分析和影像解决方案，以优化资源分配，并在不相应增加医护人员工作量的前提下改善病患预后。

同时，医疗人工智慧领域的投资和资金不断增加，加速了专业心臟解决方案的开发和商业化，并降低了创新门槛。创业投资和政府津贴尤其着重于支持心臟病学这一高影响力领域，以推动能够更精准地解读心电图和超音波心动图的演算法研发。硅谷银行2024年6月发布的报告《人工智慧驱动的医疗体验》显示，2024年初，人工智慧医疗公司获得了28亿美元的投资，其中一半的诊断投资成长都流向了心血管疾病领域。这笔资金的流入正在推动产品组合的快速扩张。正如MedTech Dive在2024年指出的那样，心血管人工智慧是已通过核准技术中第二大类别，已有98种设备在美国FDA正式註册，这表明该市场已趋于成熟，并正迅速从概念阶段过渡到临床应用阶段。

市场挑战

资料隐私和严格的监管合规是人工智慧在全球心臟病学领域扩张的主要障碍。开发高精度心血管演算法需要获取大量敏感的患者信息，包括高解析度图像和基因组图谱。然而，严格的资料保护法律体制要求复杂的匿名化流程和安全的基础设施，这显着增加了开发成本并延长了监管核准时间。这些合规负担极大地减缓了新诊断工具进入市场的速度，并限制了临床医生能够即时使用这些工具。

此外，资料外洩的风险促使医疗机构采取谨慎的态度，延后采用人工智慧整合系统。这种犹豫源于不当处理病患记录可能带来的法律和声誉后果，这些后果往往超过了早期采用带来的临床益处。根据医疗资讯管理系统协会 (HIMSS) 预测，到 2025 年，75% 的医疗专业人员将把资料隐私视为采用人工智慧技术时的最大顾虑。这种对资料安全的普遍担忧，加上医疗机构优先考虑风险规避而非在心臟科整合计算分析，正在直接阻碍市场成长。

市场趋势

人工智慧与消费级穿戴装置的融合，正在变革患者管理模式，使其从间歇性诊断转向即时追踪。先进的演算法透过分析市售智慧型手錶的数据，以医疗级灵敏度检测心律不整和结构性心臟缺陷，从而将临床监测直接延伸至日常生活。这项技术展现了利用非侵入性、消费者产生的数据制定预防性心臟照护策略的潜力，弥合了生活方式技术与临床医学之间的鸿沟。梅奥诊所2025年5月发布的摘要《人工智慧在心血管医学中的应用》指出，应用于穿戴式装置数据的人工智慧辅助筛检工具能够以93%的准确率成功识别左心室功能障碍高风险族群，凸显了消费级技术的巨大诊断潜力。

同时，人工智慧引导的机器人技术和导航在介入性心臟病学领域的应用，正在彻底改变导管介入手术的精确度。透过整合即时成像和预测性路径规划，人工智慧驱动的机器人系统使介入性心臟病专家能够以亚毫米级的精度操控复杂的血管解剖结构，从而显着降低医疗团队的辐射暴露。随着医疗机构寻求透过手术结果的标准化和自动化来提升安全性，这项技术正迅速获得商业性认可。根据Stereotaxis公司于2025年3月发布的2024财年全年财务报告，新一代磁导航机器人系统的加速应用，使其第四季销售额年增了39%。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：心臟病学人工智慧的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按组件（硬体、软体解决方案、服务）
    • 依应用领域（心律不整、中风、缺血性心臟疾病、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美心臟病学人工智慧市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：人工智慧在欧洲心臟病学领域的市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区心臟病学人工智慧市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲心臟病学人工智慧市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：人工智慧在南美洲心臟病学领域的市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球心臟病学人工智慧市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • IDOVEN
  • Dia Imaging Analysis Ltd
  • Ultromics Limited
  • Tempus AI, Inc.
  • Koninklijke Philips NV
  • UltraSight Inc.
  • HeartVista Inc.
  • RSIP Vision
  • Cleerly, Inc.
  • Viz.ai, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23989

The Global Artificial Intelligence in Cardiology Market is projected to expand from USD 838.87 Million in 2025 to USD 1665.56 Million by 2031, achieving a CAGR of 12.11%. This sector utilizes machine learning algorithms and computational analytics to decipher complex cardiovascular data, thereby enhancing early disease detection and tailoring treatment plans. Key accelerators for this market include the rising global burden of heart conditions and the critical necessity to streamline clinical workflows amidst growing patient volumes. This growth trajectory is further bolstered by the increasing confidence of medical professionals in digital health tools, evidenced by the American Medical Association's 2024 report, which indicated that 66% of physicians utilized healthcare AI in their practice, marking a substantial rise in adoption compared to the prior year.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 838.87 Million
Market Size 2031USD 1665.56 Million
CAGR 2026-203112.11%
Fastest Growing SegmentSoftware Solutions
Largest MarketNorth America

However, the market confronts significant hurdles regarding data privacy and strict regulatory compliance. The requirement to process massive volumes of sensitive patient data for algorithm training triggers security concerns and mandates adherence to rigorous legal standards, which can delay the approval and deployment of new solutions. These compliance obligations effectively slow the pace of innovation, acting as a substantial impediment to the rapid integration of these advanced diagnostic technologies into standard clinical care.

Market Driver

The escalating prevalence of cardiovascular diseases acts as the primary catalyst for the adoption of artificial intelligence in cardiology, creating a demand for sophisticated tools to manage the growing clinical and economic strain. As patient populations age and heart conditions become more complex, healthcare systems are leveraging AI to automate diagnostic workflows, minimize error rates, and control the rising costs associated with long-term cardiac care. The urgency of this shift is underscored by the American Heart Association's June 2024 advisory, 'Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050', which projects that total cardiovascular-related costs will triple to $1.8 trillion by 2050. Consequently, hospitals are aggressively integrating AI-driven predictive analytics and imaging solutions to optimize resource allocation and improve patient outcomes without proportionally increasing staff workloads.

Simultaneously, rising investments and funding for healthcare AI are accelerating the development and commercialization of specialized cardiac solutions, lowering barriers to technological innovation. Venture capital and government grants are specifically targeting the high-impact potential of cardiology, driving R&D for algorithms capable of interpreting electrocardiograms and echocardiograms with enhanced accuracy. According to Silicon Valley Bank's 'AI-Powered Healthcare Experience' report from June 2024, $2.8 billion was invested in AI healthcare companies in early 2024, with half of the recent surge in diagnostic investment directed at cardiovascular disease. This influx of capital has translated into a rapidly expanding product landscape; as noted by MedTech Dive in 2024, cardiovascular AI represented the second-largest category of cleared technologies, with 98 devices officially listed by the U.S. FDA, signaling a maturing market moving quickly from concept to clinical deployment.

Market Challenge

Data privacy and strict regulatory compliance represent a significant barrier to the expansion of the Global Artificial Intelligence in Cardiology Market. Developing high-precision cardiovascular algorithms requires access to vast repositories of sensitive patient information, including high-resolution imaging and genomic profiles. However, stringent legal frameworks regarding data protection necessitate complex de-identification procedures and secure infrastructure, which substantially inflate development costs and prolong the time required for regulatory approval. These compliance burdens effectively decelerate the pace at which new diagnostic tools can be brought to market, limiting their immediate availability to clinicians.

Furthermore, the risk of data breaches fosters a cautious approach among healthcare institutions, delaying the procurement of AI-integrated systems. This hesitation is driven by the potential legal and reputational consequences of mishandling patient records, which often outweigh the perceived clinical benefits of early adoption. According to the Healthcare Information and Management Systems Society, in 2025, 75% of healthcare professionals identified data privacy as a top concern regarding the implementation of artificial intelligence technologies. This prevailing anxiety regarding data security directly impedes market growth, as medical facilities prioritize risk mitigation over the integration of computational analytics in cardiology departments.

Market Trends

The integration of AI with consumer wearables for continuous cardiac monitoring is reshaping patient management by shifting from episodic diagnostics to real-time tracking. Advanced algorithms now analyze data from commercial smartwatches to detect arrhythmias and structural heart defects with medical-grade sensitivity, extending clinical oversight directly into daily life. This capability validates the use of non-invasive, consumer-generated data for preemptive cardiac care strategies, bridging the gap between lifestyle technology and clinical medicine. According to the Mayo Clinic's May 2025 overview, 'Artificial Intelligence (AI) in Cardiovascular Medicine', an AI-assisted screening tool applied to wearable data successfully identified individuals at risk of left ventricular dysfunction 93% of the time, confirming the high diagnostic potential of consumer-facing technology.

Simultaneously, the adoption of AI-guided robotics and navigation in interventional cardiology is revolutionizing the precision of catheter-based procedures. By synthesizing real-time imaging with predictive path planning, AI-driven robotic systems allow interventionalists to navigate complex vascular anatomy with sub-millimeter accuracy while significantly reducing radiation exposure for the medical team. This technology is rapidly gaining commercial traction as healthcare facilities seek to standardize procedural outcomes and enhance safety through automation. According to Stereotaxis's '2024 Full Year Financial Results' report from March 2025, the company recorded a 39% year-over-year revenue increase in the fourth quarter, driven by the accelerating deployment of its next-generation robotic magnetic navigation systems.

Key Market Players

  • IDOVEN
  • Dia Imaging Analysis Ltd
  • Ultromics Limited
  • Tempus AI, Inc.
  • Koninklijke Philips N.V
  • UltraSight Inc.
  • HeartVista Inc.
  • RSIP Vision
  • Cleerly, Inc.
  • Viz.ai, Inc.

Report Scope

In this report, the Global Artificial Intelligence in Cardiology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Intelligence in Cardiology Market, By Component

  • Hardware
  • Software Solutions
  • Services

Artificial Intelligence in Cardiology Market, By Application

  • Cardiac Arrhythmias
  • Stroke
  • Ischemic Heart Disease /CAD
  • Others

Artificial Intelligence in Cardiology Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artificial Intelligence in Cardiology Market.

Available Customizations:

Global Artificial Intelligence in Cardiology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Artificial Intelligence in Cardiology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Component (Hardware, Software Solutions, Services)
    • 5.2.2. By Application (Cardiac Arrhythmias, Stroke, Ischemic Heart Disease /CAD, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Artificial Intelligence in Cardiology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Artificial Intelligence in Cardiology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Component
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Artificial Intelligence in Cardiology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Component
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Artificial Intelligence in Cardiology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Component
        • 6.3.3.2.2. By Application

7. Europe Artificial Intelligence in Cardiology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Artificial Intelligence in Cardiology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Application
    • 7.3.2. France Artificial Intelligence in Cardiology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Artificial Intelligence in Cardiology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Artificial Intelligence in Cardiology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Component
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Artificial Intelligence in Cardiology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Component
        • 7.3.5.2.2. By Application

8. Asia Pacific Artificial Intelligence in Cardiology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Artificial Intelligence in Cardiology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Application
    • 8.3.2. India Artificial Intelligence in Cardiology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Artificial Intelligence in Cardiology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Artificial Intelligence in Cardiology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Artificial Intelligence in Cardiology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Application

9. Middle East & Africa Artificial Intelligence in Cardiology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Artificial Intelligence in Cardiology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Artificial Intelligence in Cardiology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Artificial Intelligence in Cardiology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Application

10. South America Artificial Intelligence in Cardiology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Artificial Intelligence in Cardiology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Artificial Intelligence in Cardiology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Artificial Intelligence in Cardiology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Artificial Intelligence in Cardiology Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. IDOVEN
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Dia Imaging Analysis Ltd
  • 15.3. Ultromics Limited
  • 15.4. Tempus AI, Inc.
  • 15.5. Koninklijke Philips N.V
  • 15.6. UltraSight Inc.
  • 15.7. HeartVista Inc.
  • 15.8. RSIP Vision
  • 15.9. Cleerly, Inc.
  • 15.10. Viz.ai, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer